Pregnant While on Targeted Therapy: — What Happens Next

The answer depends on your specific drug, your cancer's behaviour, and how far along you are. NCCN and ESMO guidance treats most targeted therapies as contraindicated in the first trimester, when organ development is happening and when exposure does the most harm. Some agents have been used in the second and third trimester in carefully selected patients under close specialist supervision — but this is not a general permission to continue, and it is not available for every drug or every cancer. Your oncologist, alongside a maternal-fetal medicine specialist, is the right team to advise you on your specific situation. Do not make this assessment alone.

Not long — and that is the hardest part of this. The first trimester is when exposure does the most harm and when pausing treatment creates the smallest gap in cancer control. Every week that passes changes what options are realistically available. Your team is not trying to rush you into something you are not ready for. They are trying to ensure you have the full range of choices while those choices still exist. Call today — you can continue the conversation at whatever pace you need once the team knows what they are dealing with.

A washout period is the time after your last dose for the drug to fall to a level unlikely to cause further harm. It is calculated from the drug's half-life — how quickly your body eliminates it. Different targeted therapies have very different half-lives: some clear in a couple of weeks, others take considerably longer. Your oncologist or clinical pharmacist can give you the exact figure for your agent. That number matters because it describes how long exposure continued after your last dose — which informs the risk assessment for the embryo.

This is the central question, and it has to be answered for your specific cancer — there is no general reply that applies to all targeted therapy patients. For some cancers at some stages, a planned pause with close monitoring during pregnancy is an accepted path. For others, the risk of stopping is high enough that it significantly limits what is realistic. Ask your oncologist directly: what does my cancer typically do without treatment over the length of this pregnancy? That answer will be one of the most important pieces of information in this entire conversation.

Some targeted therapies are associated with an increased risk of pregnancy loss, alongside the risk of developmental harm if the pregnancy continues. This does not mean a miscarriage will happen — some pregnancies exposed to targeted therapy continue without that outcome. But it is a real risk your team will discuss honestly rather than minimise. If you have already noticed bleeding or cramping, tell your team now — do not wait for a scheduled appointment.

For many patients, yes — with planning. Most guidelines recommend waiting a period after treatment ends before trying to conceive, to allow the drug to clear and to confirm the cancer remains stable. The recommended wait time is drug-specific and depends on your cancer's behaviour. If having a child after treatment is something you want to plan for, ask for a referral to an oncofertility specialist. That conversation is most useful before or at the start of treatment, when the most options — including egg or embryo freezing — are still available.